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Abstract
Context—Tobacco smoking is the leading cause of preventable morbidity and mortality in the 
United States, and smoking cessation has multiple health benefits.
Objective—The purpose of this study was to assess cigarette smokers’ perceived importance 
toward characteristics of tobacco cessation medications using a willingness-to-pay approach.
Design, Setting, and Participants—Cross-sectional analysis of data from the 2008 
HealthStyles survey, a mail-based probability sample of 5399 adults aged 18 years and older. Point 
estimates and 95% confidence intervals were calculated overall and by sociodemographic and 
smoking behavior characteristics. Multivariate Probit regression analysis was used to evaluate 
smokers’ willingness to pay in relation to perceived importance of 3 cessation medication 
characteristics: convenience of use, over-the-counter availability, and efficiency to help quit. All 
models controlled for sociodemographic characteristics, smoking behavior characteristics, and US 
regional fixed effects. A total of 914 current cigarette smokers.
Main Outcome Measures—Interest in quitting, interest in using cessation medications, and 
willingness to pay for 6 types of cessation medications.
Results—Approximately 68.4% of current cigarette smokers were interested in quitting. Among 
these individuals, 45.6% indicated that they were interested in using cessation medications, and of 
these, 47.3% indicated that they were willing to pay $150 or more out-of-pocket for these 
medications. Convenience of use and the effectiveness of these medications to help quit were 
positively associated with current smokers’ willingness to pay for $300 or more (P < .05); 
however, no association was observed for over-the-counter availability. Self-reported exposure to 
telephone quitline advertisements was also positively associated with the willingness to pay.
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Conclusions—Approximately 68% of current smokers are interested in quitting, and about half 
of those smokers interested in quitting are also interested in using cessation medications. 
Convenience of use and the medication’s effectiveness are important characteristics of cessation 
medication for smokers with quit intentions. Understanding preferences for these cessation 
medication characteristics may help inform smoking cessation efforts.
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Tobacco use remains the leading cause of preventable morbidity and mortality in the United 
States.1 Cigarette smoking is responsible for 480 000 deaths among adults annually and 
accounts for approximately 80% of deaths due to lung cancer and approximately 80% to 
90% of chronic obstructive pulmonary disease deaths.2 Despite considerable declines in 
cigarette smoking in the past 50 years, in 2012, an estimated 42.1 million adults (18.1%) 
reported current cigarette smoking.3 Given recent smoking estimates, the Healthy People 
2020 objective of reducing adult cigarette smoking prevalence to 12% or less may not be 
met.4
Quitting smoking is beneficial at any age, and smokers who quit before 35 years of age have 
mortality rates similar to persons who never smoked.5–7 While declines in smoking 
prevalence have slowed in recent years within the United States, the number of former 
smokers has exceeded the number of current smokers since 2002.8,9 Decreases in smoking 
prevalence are due in part to population-level strategies that are known to reduce tobacco use 
and include hard-hitting mass media campaigns, comprehensive smoke-free policies, 
increases in the prices of tobacco products, quitlines, and health care system changes.10–12
Addressing cessation among adult smokers can be a challenge for multiple reasons, 
including the addictive properties of nicotine in tobacco products5 and protobacco marketing 
and promotion by the tobacco industry.13 In 2010, data from the National Health Interview 
Survey indicated that among adult current smokers, 68.8% reported wanting to quit and 
52.4% reported making a quit attempt within the past year; however, among those who 
smoked for at least 2 years and former smokers who quit in the past year, only 6.2% were 
successful at quitting.14 On average, it takes approximately 10 to 14 quit attempts before 
smokers are successful at quitting.15 However, the likelihood of successful cessation can be 
increased through the use of cessation medications approved by the US Food and Drug 
Administration, including nicotine replacement therapy (patch, gum, lozenge, nasal spray, 
and inhaler), as well as oral medications, varenicline, and bupropion.10 These medications 
were used among close to 1 in 3 (30%) US adult current smokers who made an unsuccessful 
quit attempt in the past year and former smokers who quit within 2 years and who also 
reported using cessation counseling and/or cessation medications.14
While existing research has established the effectiveness of these cessation medications for 
treating nicotine dependence10 and provided the epidemiology of cessation behaviors,14 less 
is known about smokers’ perceived importance for specific characteristics of medications 
used in cessation treatments.16–20 Assessment of smokers’ perceived importance of 
cessation medication characteristics may provide an understanding about decision making 
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for cessation treatments, which can increase providers’ knowledge on how to tailor their 
discussion with patients around the use of cessation medications.
To address this gap, the current study utilized the willingness-to-pay (WTP) paradigm, 
which focuses on a person’s stated value of a good or service. While WTP has become 
increasingly popular in economic evaluation of health care interventions and programs in the 
last 2 decades, literature using this approach to investigate smokers’ perceived importance 
for characteristics of tobacco cessation medications is limited.16,19,20,21 Almost all studies 
based on the WTP approach have shown that improving effectiveness of smoking cessation 
treatments is a key attribute that is valued by smokers.16,19,20 Some studies also suggest that 
smokers would prefer improved cessation medications with reduced side effects, particularly 
prevention of weight gain,16,20 while others conclude that light smokers have a stronger 
preference for reduced length of a therapy.19
Using data from the 2008 HealthStyles survey, we assessed among current smokers, interest 
in quitting, interest in using cessation medications, and willingness to pay for 3 specific 
characteristics of cessation medications: convenience of use, availability over the counter, 
and effectiveness of the medication to help with quitting. A better understanding of this topic 
may provide information about the characteristics of tobacco cessation medications that are 
important to smokers, which may help health care providers understand smokers’ decision 
making on their use of cessation medications.
Methods
Sample
These study data are from Porter Novelli’s 2008 HealthStyles survey, a national consumer 
survey licensed by the Centers for Disease Control and Prevention. The HealthStyles survey 
has been conducted annually since 1995 and assesses exposure to health-related information 
and self-reported symptoms, risk factors, and diseases among US adults aged 18 years or 
older. The sampling and data collection were conducted by Synovate, Inc. using a consumer 
mail-based panel.
The HealthStyles surveys use a probability sample of respondents from the ConsumerStyles 
survey. The 2008 ConsumerStyles was sent to 20 000 mail panel members including a main 
sample stratified by region, household income, population density, age, and household size, 
as well as oversamples for low-income and minority respondents and households with 
children. The response rate for the 2008 ConsumerStyles was 50.6% (n = 10,108). A random 
subset (n = 7000) of adults who completed ConsumerStyles were invited to participate in the 
2008 HealthStyles; a total of 5399 responded (response rate: 77.1%). Because the focus of 
this study was cessation behaviors and preferences, the analysis was restricted to current 
smokers, who were defined as respondents who reported smoking at least 100 cigarettes in 
their lifetime and smoked every day or some days at the time of survey. In total, 4457 
HealthStyles respondents were excluded from the analysis because they were not current 
smokers. Respondents with missing data on education (n = 14) and missing data on use of 
cigarette price promotions (n = 14) were also excluded, yielding a final sample size of 914.
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Cessation outcomes—Current smokers (n = 914) were asked whether or not they were 
interested in trying to quit smoking cigarettes for good. Interested in quitting was defined as 
current smokers who responded being interested or maybe interested in quitting smoking. 
Interested in cessation medications was defined as current smokers who were interested or 
maybe interested in quitting and who responded “yes” to interest in using cessation 
medications. Those who reported that they were interested in using medications to quit 
smoking were then asked, “What is the most you would be willing to pay for that medication 
out of your own pocket if you were purchasing medication to help quitting smoking?” There 
were 6 response options: “$150,” “$300,” “$450,” “$600,” “$850,” and “none of the above.” 
For WTP, a dichotomous variable was created with “1” denoting individuals willing to pay 
$300 or more and a “0” denoting individuals willing to pay the lower amount of $150. 
“None of the above” respondents (n = 158) were excluded from this regression analysis 
because of the ambiguity of this response. The threshold of $300 dollars was determined by 
the distribution of the data, as roughly 25% of respondents who were eligible for the WTP 
analysis would be willing to pay $300 or more out of pocket for cessation medication.
Sociodemographic Characteristics—Sociodemographic characteristics included sex 
(male or female), age group (18–24, 25–54, ≥55 years), race/ethnicity (white non-Hispanic, 
black non-Hispanic, other non-Hispanic, Hispanic), educational attainment (high school or 
less, some college, college or more), marital status (married, formerly married, never 
married, domestic partnership), annual household income (<$15 000, $15 000–$39 999, $40 
000–$59 999, ≥$60 000), and health insurance status (yes or no). In addition, regional fixed 
effects were generated for US Census regions (Northeast, Midwest, West, and South) and 
used to control for regional time-invariant characteristics influencing smoking, such as 
antismoking sentiment.
Cessation correlates—Cessation-related variables that were examined included interest 
in using prescription tablets or nicotine gum, patches, inhalers, nasal sprays, and/or lozenges 
in helping quit smoking (yes or no); smokers’ perceived importance of the cessation 
medication characteristics, which include importance of medication costs, convenience of 
use, availability over the counter, and effectiveness of the medication (each variable taking a 
value of between 1 and 5, with 5 being “very important”). Confidence in the ability to pay 
was also measured and refers to smokers’ belief that they can actually pay the amount that 
they responded they are willing to pay and was measured on a scale of 1–4, with 4 being 
“very confident.” Exposure to a telephone quitline advertisement in the past 30 days and use 
of cigarette price promotions (eg, coupons, rebates, buy 1 get 1 free, “dollar-off,” and 2 for 
1) when purchasing cigarettes (“never,” “rarely,” “sometimes,” “often,” “all of the time”) 
were also assessed.
Analysis
All statistical analyses were conducted using STATA (v12). Point estimates and 95% 
confidence intervals (CI) were generated using data weighted to provide estimates for the 
US adult population. Pear-son χ2 tests were used to test for differences between groups at a 
significance level of P value of less than .05. Multivariate Probit analyses were conducted 
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using each of 3 dependent variables: (1) interested in quitting; (2) interested in using 
cessation medications; and (3) willingness to pay $300 or more for medications.
Probit models were used in all regressions because the overall model F-statistics were higher 
for all specifications than those from logistic models. The joint significance of the model for 
interest in quitting had an F-statistic of 2.34 (P ≤ .001) for Probit versus 2.16 (P ≤ .001) for 
Logistic; for interest in using medicine to quit smoking of 3.50 (P ≤ .001) for Probit versus 
3.02 (P ≤ .001) for Logistic; and for higher WTP of 1.54 (P ≤ .05) for Probit versus 1.26 (P 
> .10) for Logistic. These F statistics suggest that probabilities in the data are most 
appropriately modeled using the standard normal distribution function rather than the 
logistic distribution. Probit coefficients were transformed to marginal effects, which is 
interpreted as the difference in the investigated group compared with the reference group for 
categorical independent variables.22 The defined sociodemographic and cessation variables 
were included as covariates in the model to identify predictors of these 3 cessation measures.
Results
Sociodemographic and smoking behaviors by interest in quitting, interest in cessation 
medications, and WTP
A total of 914 (19.5%) current cigarette smokers were identified in the 2008 HealthStyles 
survey (see Supplemental Digital Content Table 1, available at http://links.lww.com/JPHMP/
A172). Among these individuals, 612 (68.4%) reported an interest in quitting. 
Sociodemographic and smoking behaviors did not statistically differ by smokers’ interest in 
quitting. Among those interested in quitting, 295 (45.6%) expressed an interest in using 
cessation medications (see Supplemental Digital Content Table 2, available at http://
links.lww.com/JPHMP/A173). Compared with those not interested, those interested in using 
cessation medications were more likely to be non-Hispanic white (80.5%) and have an 
annual household income of $60 000 or more (29.2%) and less likely to be non-Hispanic 
black (6.2%) and have an annual household income between $15 000 and $39 999 (29.6%). 
Interest in using cessation medications was also positively associated with the proportion of 
smokers’ responding that they frequently used promotional offers when purchasing 
cigarettes. Among those who were interested in cessation medications (47.3%), were willing 
to pay $150 or more for out-of-pocket expenses, while the rest (158) did not provide a figure 
for their WTP (see Supplemental Digital Content Table 3, available at: http://links.lww.com/
JPHMP/A174). Compared with those who did not provide a WTP, smokers who reported 
WTP were more likely to have some college education (62.2% vs 41.4%), to have seen 
quitline advertisements (66.8% vs 54.1%), or to have some confidence in their WTP (47.0% 
vs 27.1%), but they were less likely to have high school education or less (29.5% vs 46.8%) 
or to be unconfident in their WTP (8.6% vs 26.1%).
Correlates of smokers’ interest in quitting, interest in cessation medications, and WTP
After controlling for covariates, the proportion of smokers interested in quitting decreased 
with age (Table). Specifically, compared with smokers aged 55 years and older, interest in 
quitting was 22.2% (18.0 Probit regression coefficient; 95% CI, 5.0–31.1) higher among 
smokers aged 18 to 24 years, and 12.2% (9.9; CI, 1.9–17.8) higher among smokers aged 25 
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to 54 years. Similarly, compared with non-Hispanic whites, non-Hispanic black respondents 
were 12.6% (10.2; CI, 2.9–17.5) more likely to be interested in quitting.
Compared with non-Hispanic whites, non-Hispanic blacks were 69.4% (32.3; CI, 21.1–43.5) 
less likely to be interested in using cessation medications (Table). Interest in cessation 
medications was 75.4% (35.1; CI, 20.3–50.0) lower among smokers of other races or 
ethnicities. Compared with those with annual household income of $60 000 or more, 
smokers with a household income between $15 000 and $39 999 were 39.8% (17.8; CI, 5.7–
29.9) less interested in cessation medications. The use of promotional offers when 
purchasing cigarettes among smokers was associated with higher interest in using cessation 
medication. Compared with smokers who had never used promotional offers, those who 
reported “rarely” or “sometimes” using promotional offers were 55.2% (25.7; CI, 9.6–41.8) 
more interested in medications, while those who reported “often” or “always” used 
promotional offers were 52.6% (24.5; CI, 9.4–39.5) more likely to be interested.
Differences in WTP among those who were interested in using medications to quit were 
observed with respect to smokers’ sociodemographic and smoking behavioral 
characteristics. Compared with non-Hispanic whites, non-Hispanic black respondents were 
68.5% (24.9; CI, 3.3–46.5) less likely to pay $300 or more out of pocket. Similarly, smokers 
with an annual household income between $15 000 and $39 999 were 89.1% (32.4; CI, 1.6–
48.8) less likely to pay $300 or more for cessation medications than those with a household 
income of $60 000 or more. However, smokers who had seen quitline advertisements in the 
past 30 days were 50.6% (18.4; CI, 1.3–35.4) more likely to pay $300 or more out of pocket 
for cessation medications.
Compared with smokers who reported convenience of use as less important (1 and 2 in the 
scale of importance), those who reported convenience as very important were 59.4% (21.6; 
CI, 5.8–37.4) more likely to pay $300 or more, and those who reported convenience of use 
as somewhat important were 122.1% (44.4; CI, 25.6–63.3) more likely to pay $300 or more. 
With respect to the effectiveness of the products, smokers who reported this characteristic as 
“very important” were 45.4% (16.5; CI, 0.8–32.1) more likely to pay $300 or more when 
compared with those who reported this was “somewhat important.” In addition, the level of 
confidence in the self-reported WTP was also positively associated with the likelihood of 
having a WTP of $300 or more, with the likelihood rising by 41.8% (15.2; CI, 6.6–23.8) for 
each unit increase in the level of confidence.
Discussion
Our findings show that approximately 68% of current smokers are interested in quitting and 
close to half of these individuals are interested in using medications to assist with cessation. 
In addition, young smokers and non-Hispanic blacks were found to be more interested in 
quitting; although we found that non-Hispanic Blacks were less interested in using cessation 
medications than other racial/ethnic populations and among those interested in using 
medications, non-Hispanic Blacks were less willing to pay more for medications.
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Consistent with existing literature, we found that smokers who have a desire to quit value the 
importance of cessation medications with successful quit rates,16,19,20 as the effectiveness of 
cessation products was associated with higher WTP. It is also important to note that none of 
the respondents reported low importance for the effectiveness of cessation medications, 
which validates the rationale that smokers do not want to pay for and utilize medications that 
are not effective in helping them quit. The negative association found between importance of 
medications being available over the counter and WTP to pay $300 or more among the 
current smokers who were interested in quitting is not particularly surprising and provides 
partial support for the validity of the WTP measures, as very few over-the-counter 
medications would cost more than $300. However, it should be noted that this finding does 
not necessarily mean that making the cessation medications available over the counter would 
not be valued by those who are interested in quitting.
We found that smokers who want to use medications to quit also value the importance of 
their convenience to use. This finding may provide a partial explanation as to why use of 
nicotine inhalers is very low, as they may not be as convenient to use as other types of 
cessation medications.18 In addition, we found that confidence in the ability to pay was 
positively associated with the maximum amount that respondents indicated they are willing 
to pay. This finding provides evidence of the validity of the survey measures and also 
suggests that smokers who are interested in quitting may be able and willing to financially 
commit to changing the behavior. However, smokers interested in quitting with a household 
income between $15,000 and $39,999 were significantly less likely to report having interest 
in using medications and significantly less likely to be willing to pay $300 or more. These 
findings suggest the importance of socioeconomic status of smokers when determining 
cessation treatment options. Finally, it is also interesting to note that smokers who reported 
seeing telephone quitline advertisements were also willing to pay more for cessation 
medications. This finding suggests that in addition to a desire to quit, smokers who are 
prompted by cessation education and media communication may be willing to take action to 
change the behavior.
It should be noted that this study was informed by the 2008 update to the US Public Health 
Service Clinical Practice Guideline: Treating Tobacco Use and Dependence to understand 
the economics of decision making for smoking cessation. Therefore, our findings are based 
upon smokers’ perceived importance of cessation medication characteristics. The 2008 
update to the US Public Health Service Clinical Practice Guideline: Treating Tobacco Use 
and Dependence recommends that clinicians and health care delivery systems consistently 
identify and document tobacco use status and treat every tobacco user seen in a health care 
setting.10 These guidelines also recommend individual, group, and telephone counseling; the 
7 first-line medications for tobacco dependence that are approved by the Food and Drug 
Administration; and provision of coverage for these treatments by health care systems, 
insurers, and purchasers to increase successful cessation attempts.10
In addition, several provisions in the Affordable Care Act provide opportunities for 
expanding state Medicaid cessation coverage.23–25 Effective October 2010, section 4107 of 
the Affordable Care Act required state Medicaid programs to cover tobacco cessation 
counseling and pharmacotherapy for pregnant women with no cost sharing. Effective 
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January 2014, through provisions of the section 2502 of the Affordable Care Act, state 
Medicaid programs can no longer exclude Food and Drug Administration–approved 
cessation medications, including over the counter medications, from Medicaid drug 
coverage. Although these provisions should increase Medicaid enrollees’ access to cessation 
medications, the extent to which it will do so remains unclear, particularly depending on 
state actions, such as whether or not cessation medications will be added to preferred drug 
lists, and the removal of barriers to accessing these medications. Therefore, additional 
research is needed to understand the dynamics of cessation efforts among smokers given the 
new health care legislation.
While the present study provides some novel findings in regard to what smokers’ value as 
important attributes of cessation medications, there are some limitations. First, data were 
self-reported, and thus the findings may be subject to recall bias, in particular, for 
respondents who reported seeing Quitline ads and using promotional offers. However, it 
should be noted that among smokers in our study, close to 68.4% reported having an interest 
in quitting, which is comparable with an estimate from the 2010 National Health Interview 
Survey (68.8%).14 It should also be noted that of the 914 smokers, only 123 were interested 
in quitting by using medications and were willing to pay $150 or more for cessation 
medications, a monetary threshold that may be too high for WTP for cessation medications. 
Second, the study measures were also limited with respect to the range of costs that smokers 
are willing to pay, and the time frame and frequency of payment, which may have affected 
how smokers responded to the amount they would be willing to pay. In addition, 
“hypothetical bias” may exist when respondents were asked to present their WTPs without 
actual monetary transfers. However, existing experiments have shown that the “cheap talk” 
design as utilized in this study was successful in eliciting responses to hypothetical valuation 
questions that were indistinguishable from responses to valuation questions involving actual 
payments.26 Although the study was conducted using 2008 data, it is unlikely that the value 
for characteristics of medication would change. However, additional studies based on more 
recent data are needed. Finally, since the Health-Styles is a cross-sectional survey, causal or 
temporal relationships could not be established.
In conclusion, the findings from this study indicate that a large proportion of adult current 
smokers who have an interest in quitting smoking also have an interest in using effective 
cessation medication and are willing to pay a substantial amount for certain features of 
cessation medications to obtain them. Smokers who are interested in quitting may perceive 
certain characteristics as important, such as medication’s effectiveness and the convenience 
in using cessation medications. While a contribution of this study is a better understanding 
of smokers’ WTP, the findings warrant additional research to test hypotheses on perceived 
importance of cessation treatments on actual quitting behaviors, using discrete choice 
experiments and longitudinal study designs. Because there are 45 million adult smokers, 
understanding the characteristics of cessation interventions valued by smokers who want to 
quit may help health care professionals in their efforts to assist in cessation and promote the 
use of known effective cessation medications.
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